Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Withdrawn
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of decitabine and how well it
works when given together with enzalutamide in treating patients with castration resistant
prostate cancer that has spread to other places in the body. Androgen can cause the growth of
prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgen made by
the body. Decitabine may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving decitabine and enzalutamide may work better in treating
participants with castration resistant prostate cancer.